@demimentor's peptide bacteriostatic water questions, answered

What did @demimentor actually say?

They gave a three-week retatrutide update and admitted they're lost. The honest summary: two kilos gained, protein hit, training consistent, but "I feel no different." They flagged a mixing error early on, specifically reconstituting with three mils of bacteriostatic water, and reported dosing 10 to 20 units three times per week, which they calculated as roughly 500 mcg per injection. They're not making health claims here. They're asking for help. That's actually a more honest TikTok than most.

The hashtags suggest they're deep in peptide communities where dosing advice circulates freely, often without clinical oversight. The creator seems to be comparing their experience to GLP-1 receptor agonist effects they've had before, saying they know "that feeling you're meant to get" and aren't getting it with retatrutide. That comparison matters for understanding what they expected.

Does the science back up their expectations?

Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. In the Phase 2 trial published by Jastreboff et al. (2023, New England Journal of Medicine), participants on the highest dose saw up to 17.5% body weight reduction over 24 weeks. But here's the catch: that was in a controlled clinical setting with pharmaceutical-grade drug, verified doses, and supervised titration starting low and increasing gradually over months.

Three weeks is not enough time to evaluate any GLP-1 class compound. The Jastreboff trial showed meaningful weight loss curves that didn't really diverge from placebo until weeks 8 to 12. Expecting the sensation of appetite suppression at week three, at a dose that hasn't been clinically validated in any published study at that exact frequency, is setting yourself up for disappointment. The creator's frustration is understandable. The timeline expectation is off.

What did they get wrong, and what did they actually get right?

The reconstitution math deserves scrutiny. Mixing with three mils of bacteriostatic water isn't automatically wrong, but the concentration it produces depends entirely on the vial's labeled peptide quantity, which they didn't state. If they started with a 5 mg vial and added 3 mL BW, each 10 units on an insulin syringe delivers approximately 167 mcg. Their 500 mcg estimate per injection only holds at specific starting quantities. The math could be right or significantly off depending on what's actually in the vial.

What they got right: flagging the early mixing error themselves, hitting protein targets, and training consistently. These are legitimate variables that affect outcomes. They're also right to be skeptical of their own results rather than just blaming the compound. The weight gain of two kilos over three weeks while eating in a surplus is almost certainly caloric, not a drug failure. Retatrutide does not override a sustained caloric surplus, even in clinical trials.

What should you actually know?

A few things the peptide community rarely says clearly. First, compounded retatrutide is not the same as investigational pharmaceutical retatrutide used in trials. Purity, concentration accuracy, and sterility in compounded peptides vary considerably, and no compounded version has regulatory approval. Second, the triple agonist mechanism means the glucagon receptor component actually increases energy expenditure, but it also means the pharmacology is more complex than single GLP-1 agonists. Individual response variation is real and under-discussed.

Third, "I'm hitting my protein and training" while also "eating way too much" is a contradiction that no peptide resolves. GLP-1 agonists reduce appetite in clinical settings, but that appetite suppression typically builds over weeks to months during titration, according to findings from Müller et al. (2022, Nature Metabolism). Starting at a fixed dose and expecting immediate satiety blunting comparable to an established GLP-1 drug is an unrealistic benchmark, especially at three weeks.